This acquisition highlights Valeant Canada's increasing importance as a leader in Canadian surgical ophthalmology
LAVAL, QC, Nov. 4, 2014 /CNW Telbec/ - Valeant Canada today announced that its affiliate has completed the acquisition of CROMA Pharma Canada LTD, a subsidiary of CROMA Pharma GmbH, the private global pharmaceutical and surgical company based in Austria and specializing in ophthalmology, among a variety of other fields.
This acquisition will provide Valeant Canada with an opportunity to introduce a range of complementary products into the Canadian market which will be integrated into its Bausch + Lomb Canada division.
The acquisition of new and innovative products from CROMA, such as EyeCEE Intra ocular lenses, EyeFill viscoelastics, Cornea Protect and Capsular Retention Ring will expand Bausch + Lomb Canada's ophthalmic portfolio. Bausch + Lomb Canada, a division of Valeant Canada, already offers its Canadian customers the finest range of eye health products, including enVista and Akreos family of IOL's, Crystalens AO, SofPort AO, Stellaris Phaco, Retina Platform and Victus.
"The acquisition of CROMA further demonstrates Valeant's commitment to investment in innovation in the Eye Health space. It will clearly expand the breadth and depth of our surgical ophthalmology portfolio for our customers and Canadian patients,'' said Charles Perez, Vice-President and General Manager of Bausch & Lomb Canada.
About Bausch + Lomb
Bausch + Lomb is solely dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple yet powerful: Helping you see better to live better. The company is one of the best-known and most respected healthcare brands in the world, offering the widest and finest range of eye health products including contact lenses and lens care products, pharmaceuticals, intraocular lenses and other eye surgery products.
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Canada can be found at www.valeantcanada.com.
The news release is available at www.cnw.ca.
SOURCE: Valeant Canada
For further information: Media Contact: Marie-Christine Garon, Valeant Canada, [email protected], 514-409-0031